Trelegy Ellipta Powder
Product Images NDC 0173-0887

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Trelegy Ellipta (NDC 0173-0887). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ff Chemical Structure (Trelegy Ellipta Spl Graphic 01)

FDA Label Image

Umeclidinium Chemical Structure (Trelegy Ellipta Spl Graphic 02)

FDA Label Image

Vilanterol Chemical Structure (Trelegy Ellipta Spl Graphic 03)

FDA Label Image

Figure 1. Impact Of Intrinsic Factors On The Pharmacokinetics (pk) Of Fluticasone Furoate (ff) And Vilanterol (vi) Following Administration As Fluticasone Furoate/vilanterol Combination (Trelegy Ellipta Spl Graphic 04)

FDA Label Image

Figure 2. Impact Of Coadministered Drugsa On The Pharmacokinetics (pk) Of Fluticasone Furoate (ff) And Vilanterol (vi) (Trelegy Ellipta Spl Graphic 05)

FDA Label Image

Figure 3. Impact Of Intrinsic And Extrinsic Factors On The Systemic Exposure Of Umeclidinium (Trelegy Ellipta Spl Graphic 06)

This text is a population description indicating recommendations for dose adjustments or caution when administering drugs for patients with severe renal or hepatic impairment. It also advises on the interaction of interacting drugs such as Ketoconazole and Verapamil with PK, AUC, Cmax and Crmax values, with fold changes or 90% confidence interval. The document also includes a chart showing changes relative to reference at different time intervals.*

FDA Label Image

Trelegy Fig 4 (Trelegy Ellipta Spl Graphic 07)

This text lists different parameters related to the effect of certain factors in drug administration, such as renal and hepatic impairment, CYP2D6 inhibition, and P-gp transport. It also includes the recommended action in each case, which is generally to not adjust the dose.*

FDA Label Image

Trelegy Fig 5 (Trelegy Ellipta Spl Graphic 08)

This appears to be a graph or chart displaying the LS Mean Change from Baseline in mL over time (in hours) for two different treatments - one with umeclidinium and fluticasone furoate/vilanterol and another with placebo and fluticasone furoate/vilanterol. The graph indicates that the treatment with umeclidinium and fluticasone furoate/vilanterol resulted in a greater change from baseline over time compared to the placebo and fluticasone furoate/vilanterol treatment. The specific context or purpose of this information is not available.*

FDA Label Image

Figure 6. Least Squares (ls) Mean Change From Baseline In Trough Fev1 (ml) (Trelegy Ellipta Spl Graphic 09)

FDA Label Image

Trelegy-ellipta-spl-graphic-10.jpg (Trelegy Ellipta Spl Graphic 10)

FDA Label Image

Figure A (Trelegy Ellipta Spl Graphic 11)

This is a graph comparing the change from baseline in mL of two medication treatments, TRELEGY ELLIPTA 100/62.5/25 mcg and Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg, over the course of 24 weeks. The graph shows that TRELEGY ELLIPTA resulted in a significant increase in mL compared to FF/VI.*

FDA Label Image

Figure B (Trelegy Ellipta Spl Graphic 12)

FDA Label Image

Figure C (Trelegy Ellipta Spl Graphic 13)

This description is not-available since it only lists the names of the items and does not provide any characteristics or properties about them.*

FDA Label Image

Figure D (Trelegy Ellipta Spl Graphic 14)

FDA Label Image

Figure E (Trelegy Ellipta Spl Graphic 15)

FDA Label Image

Figure F (Trelegy Ellipta Spl Graphic 16)

FDA Label Image

Figure G (Trelegy Ellipta Spl Graphic 17)

FDA Label Image

Figure H (Trelegy Ellipta Spl Graphic 18)

FDA Label Image

Figure I (Trelegy Ellipta Spl Graphic 19)

FDA Label Image

Figure J (Trelegy Ellipta Spl Graphic 20)

FDA Label Image

Figure K (Trelegy Ellipta Spl Graphic 21)

FDA Label Image

Figure L (Trelegy Ellipta Spl Graphic 22)

FDA Label Image

Trelegy Ellipta 30 Dose Carton (Trelegy Ellipta Spl Graphic 23)

FDA Label Image

Trelegy Ellipta Spl Graphic 24

FDA Label Image

Trelegy Ellipta Spl Graphic 25

FDA Label Image

Trelegy Ellipta Spl Graphic 26

TRELEGY is a prescription medication that comes in inhalation powder form for oral inhalation only. It contains a combination of three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. Each package contains two foil strips of 30 blisters each, providing a total of 30 doses or 60 blisters. The blisters on one strip contain 100 mcg of fluticasone furoate and lactose monohydrate, while the blisters on the other strip contain 62.5 mcg of umeclidinium, 25 mcg of vilanterol, magnesium stearate, and lactose monohydrate. The medication is intended for those with a prescription and the NDC number is 0173-0887-10.*

FDA Label Image

Trelegy Ellipta Spl Graphic 27

TRELEGY ELLIPTA is an inhalation powder medication that contains a combination of fluticasone furoate, umeclidinium, and vilanterol. It is used for oral inhalation only and comes with 2 strips of 30 blisters each, with each blister containing either 200 mg of fluticasone furoate and lactose monohydrate or 62.5 mcg of umeclidinium, 25 mcg of vilanterol, magnesium stearate, and lactose monohydrate. The package also includes an ELLIPTA inhaler with 30 doses (60 blisters total).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.